Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.7 USD | +1.40% |
|
-1.59% | +14.94% |
06-25 | Oppenheimer Initiates Keros Therapeutics at Outperform With $102 Price Target | MT |
06-18 | Keros Therapeutics Names Chief Executive Officer Jasbir Seehra as Board Chair | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.94% | 1.65B | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- KROS Stock
- News Keros Therapeutics, Inc.
- Oppenheimer Initiates Keros Therapeutics at Outperform With $102 Price Target